The effect of Silybin capsule in the treatment of non-alcoholic steatohepatitis
-
摘要: 目的探讨水林佳胶囊治疗非酒精性脂肪性肝炎(NASH)的临床疗效。方法回顾性研究采用水林佳治疗确诊为NASH152例患者,疗程均达到3月,依据治疗前后体重变化情况将其分为两组,体重下降者为观察组,体重未下降者为对照组,观察治疗前后患者症状、肝功能、血脂、血糖及肝脏彩超变化。结果观察组肝区不适、乏力、厌食、腹胀改善情况优于对照组(P<0.01或P<0.05)。观察组及对照组均能明显降低ALT、AST、TC、LDL-L,并减轻肝脏彩超脂肪变性,但观察组还明显降低TG、GGT,并且在改善肝功能、血脂、血糖、肝脏彩超方面明显优于对照组(P<0.01,P<0.001或P<0.05)。结论水林佳胶囊能有效改善NASH患者的临床症状、肝功能、血脂、血糖及其肝脏影像学表现,但如果伴有体重下降则疗效更为明显。
-
关键词:
- 非酒精性,脂肪性肝炎 /
- 水飞蓟宾 /
- 疗效观察
Abstract: Objective To observe the clinical effect of Silybin capsule in the treatment of non-alcoholic steatohepatitis.Methods 152 cases of non-alcoholic steatohepatitis treated with Silybin capsule for 3 months were studied retrospectively.Patients were divided into weight loss group and control group based on the changes in body weight before and after treatment.The changes in symptom, liver function tests, blood lipid, FBG and liver ultrasound were analyzed.Results The rate of symptoms alleviation such as pain in the hepatic region, fatigue, anorexia and abdominal distension in the weight loss group were higher than the control group (P<0.05 or P<0.01) .The concentrations of the ALT, AST, TC and LDL-L were reduced, and the liver ultrasound appearance of all the patients was improved.The remission of TG, GGT, liver function, LDL-L, FBG and the liver steatosis in ultrasound examination were better in the weight loss group than the controls (P<0.01, P<0.001 or P<0.05) .Conclusion Silybin capsule can effectively ameliorate symptoms, improves liver function tests and liver steatosis, and lowers FBG and blood-lipid in the presence of weight loss.-
Key words:
- nonalcoholic steatohepatitis /
- Silybin /
- therapeutic effect
-
[1]王宝恩, 谢贤春, 段钟平.水飞蓟宾磷脂复合物治疗脂肪肝临床对照研究[J].药品评价, 2007, 2 (4) :68-70. [2]中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志, 2006, 14 (3) :161-163. [3]范建高.脂肪性肝病的流行现状及其自然史[J].现代实用医学, 2006, 7 (18) :445-447. [4]Rajnarayana K.Reddy MS, Vidyasagar J, et al.Study on the influence of silymairn perteratment on metabolism and disposition of metron-idazole[J].Arznelmittelforschung, 2004, 54 (2) :109-113. [5]Sailer R, Meier R, Brignoli R.The use of silymarin in the teratment of liver diseases[J].Drugs, 2001, 61 (14) :2035-2063. [6]WellingtonK, JarvisB.Silymarin:a review of its clinical porperties in the management of hepatic disodrers[J].BioDrugs, 2001, 15 (7) :465-489. [7]陈正跃, 吴子钊, 许建文, 等.水飞蓟宾-磷脂酰胆碱复合物与水飞蓟宾对四氯化碳所致小鼠急性肝损伤保护作用的对比[J].中国生化药物杂志, 2004, 25 (4) :221-223.
本文二维码
计量
- 文章访问数: 3352
- HTML全文浏览量: 21
- PDF下载量: 840
- 被引次数: 0